Metastatic Renal Cell Carcinoma Change Vascularity

Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). A case of a 32-year-old woman with mRCC is presented. These tumors could change vascularity by administration of molecular agents. We could select a drug timely based on findings of comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Azuma, Takeshi, Matayoshi, Yukihide, Sato, Yohsuke, Sato, Yujiro, Nagase, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437274/
https://www.ncbi.nlm.nih.gov/pubmed/22970402
http://dx.doi.org/10.1155/2012/654617
_version_ 1782242768413786112
author Azuma, Takeshi
Matayoshi, Yukihide
Sato, Yohsuke
Sato, Yujiro
Nagase, Yasushi
author_facet Azuma, Takeshi
Matayoshi, Yukihide
Sato, Yohsuke
Sato, Yujiro
Nagase, Yasushi
author_sort Azuma, Takeshi
collection PubMed
description Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). A case of a 32-year-old woman with mRCC is presented. These tumors could change vascularity by administration of molecular agents. We could select a drug timely based on findings of computed tomography. To our knowledge, this is the first report that tumor's character change induced by molecular targeted agents can be detected and the efficacy of molecular targeted agents can be predicted.
format Online
Article
Text
id pubmed-3437274
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34372742012-09-11 Metastatic Renal Cell Carcinoma Change Vascularity Azuma, Takeshi Matayoshi, Yukihide Sato, Yohsuke Sato, Yujiro Nagase, Yasushi Case Rep Urol Case Report Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). A case of a 32-year-old woman with mRCC is presented. These tumors could change vascularity by administration of molecular agents. We could select a drug timely based on findings of computed tomography. To our knowledge, this is the first report that tumor's character change induced by molecular targeted agents can be detected and the efficacy of molecular targeted agents can be predicted. Hindawi Publishing Corporation 2012 2012-08-30 /pmc/articles/PMC3437274/ /pubmed/22970402 http://dx.doi.org/10.1155/2012/654617 Text en Copyright © 2012 Takeshi Azuma et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Azuma, Takeshi
Matayoshi, Yukihide
Sato, Yohsuke
Sato, Yujiro
Nagase, Yasushi
Metastatic Renal Cell Carcinoma Change Vascularity
title Metastatic Renal Cell Carcinoma Change Vascularity
title_full Metastatic Renal Cell Carcinoma Change Vascularity
title_fullStr Metastatic Renal Cell Carcinoma Change Vascularity
title_full_unstemmed Metastatic Renal Cell Carcinoma Change Vascularity
title_short Metastatic Renal Cell Carcinoma Change Vascularity
title_sort metastatic renal cell carcinoma change vascularity
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437274/
https://www.ncbi.nlm.nih.gov/pubmed/22970402
http://dx.doi.org/10.1155/2012/654617
work_keys_str_mv AT azumatakeshi metastaticrenalcellcarcinomachangevascularity
AT matayoshiyukihide metastaticrenalcellcarcinomachangevascularity
AT satoyohsuke metastaticrenalcellcarcinomachangevascularity
AT satoyujiro metastaticrenalcellcarcinomachangevascularity
AT nagaseyasushi metastaticrenalcellcarcinomachangevascularity

Ejemplares similares